ResearchMoz

Clinical Supply Chain Management - Technologies such as IVRS, CTMS, EDC and RFID Enhance Drug Supply Management

GBI Research
Published Date » 2012-08-22
No. Of Pages » 56
   
 GBI Research, leading business intelligence provider has released its latest research report, entitled Clinical Supply Chain Management Technologies such as IVRS, CTMS, EDC and RFID Enhance Drug Supply Management. The report focuses on the current scenario of clinical supply chain management. Key segments of the clinical supply chain which are covered in the report include labeling, packaging, warehousing, logistics, distribution and destruction of investigational products.  
   
 There has been an increase in the number of developmental drugs, and an expansion in clinical trial sites and the complexity of clinical trials. There has also been an increase in the total number of procedures undertaken per clinical trial.  
   
 Clinical Supply Chain Management (CSCM) is...
Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7

2 Clinical Supply Chain Management - Introduction 8

3 Clinical Supply Chain Management - Overview 9

3.1 Overview of Clinical Supply Chains 9
3.1.1 Evolution of Clinical Supply Chains 11

4 Clinical Supply Chain Management - Industry Analysis 12
4.1 Capital Requirement 12
4.2 Skilled Workforce 13
4.3 Competition Among Existing Players 13

5 Clinical Supply Chain Management - Drivers and Restraints 14
5.1 Drivers 14
5.1.1 Increasing Concern for Pharmaceutical Companies to Improve R&D Outcomes 14
5.1.2 Geographic Expansion for Conducting Clinical Trials 14
5.2 Restraints 15
5.2.1 Complex Regulatory System 15
5.2.2 High Cost Involved for Entering the Market and Maintaining Processes 15
5.2.3 Proper Visibility of Products in the Supply Chain (Inventory Visibility and Traceability) 15

6 Clinical Supply Chain Management - Components of the Clinical Supply Chain 16
6.1 Labeling 16
6.2 Packaging 17
6.2.1 Blister Packaging 17
6.2.2 Plastic Bottles 18
6.2.3 Labels and Accessories 18
6.2.4 Pouches and Strip Packs 18
6.2.5 Caps and Closures 18
6.2.6 Secondary Containers 18
6.2.7 Others 18
6.3 Logistics 19
6.3.1 Focus Areas for Logistics 20
6.4 Distribution Models 21
6.4.1 Outsource 22
6.4.2 Build 22
6.4.3 Acquisition 22
6.4.4 Direct Shipping 23
6.4.5 Co-Development 23
6.5 Inventory Management 23
6.6 Destruction and Disposal of Waste 24
6.6.1 Recording of Destruction 24
6.6.2 Methods of Destruction 24

7 Clinical Supply Chain Management - CROs Operate in Clinical Trial Supplies 25
7.1 Key Reasons for Outsourcing of Clinical Trials and Research Processes 25
7.1.1 Different Strategies Adopted by Pharmaceutical Companies to Increase Efficiency 26
7.1.2 Increase in the R&D Costs Against Revenue Growth is a Reason for Outsourcing Clinical Trials to CROs 26
7.1.3 Increasing Drug Failure Rates a Concern for Pharmaceutical Companies 27
7.1.4 Outsourcing Clinical Trials to CROs in Order to Decrease the Time Required for Launching the Product in the Market 27
7.1.5 Outsourcing to Site Management Organizations (SMO) 28
7.1.6 Minimization of Development Risks Through Risk Sharing with CROs is One of the Key Reasons for Outsourcing 29
7.1.7 CROs Can Effectively Manage the Trends in Regulations Governing Clinical Trials 30
7.2 Factors Leading to CSMO Growth 30

8 Clinical Supply Chain Management - Key Challenges for Effective and Efficient Supply Chain Management 31
8.1 Key Factors for Efficient Supply Chain Management in Clinical Trials 31
8.1.1 Planning Issues 31
8.1.2 Manufacturing Issues 31
8.1.3 Distribution Issues 32
8.1.4 Visibility Issues 32
8.1.5 Technical Integration with the Vendors 32

9 Clinical Supply Chain Management - Technological Landscape 33
9.1 Information Technology in R&D 33
9.1.1 Data Management 34
9.1.2 Clinical Data Management System 34
9.1.3 Clinical Data Management Outsourcing 35
9.1.4 Deals in Clinical Trial Data Management Outsourcing 35
9.2 IVRS/IWRS 36
9.2.1 IVRS Provides Real-Time Clinical Trials Data Tracking for the Following 37
9.2.2 Case Study 39
9.3 Clinical Data Management Systems (CDMS)/Clinical Trial Management Systems (CTMS) 40
9.4 Electronic Data Capture (EDC) 41
9.5 Clinical Trial Management System (CTMS) 41
9.6 Radio Frequency Identification (RFID) 42

10 Clinical Supply Chain Management - Regulatory Landscape 43
10.1 The US 43
10.1.1 Important Regulations by the FDA in Proposal 43
10.1.2 FDA Motivating CROs to Use Adaptive Design in Drug Development 43
10.2 Europe 44
10.2.1 The New Pharmacovigilance Legislation 45
10.2.2 Reasons for Passing the New Legislation 45
10.3 Emerging Markets 45
10.4 India 46
10.4.1 Potential Advantages of the Indian CRO Market 46
10.5 China 47
10.5.1 Potential Advantages of the Chinese CRO Market 47

11 Clinical Supply Chain Management - Profiles of Key Players and Key Deals 49
11.1 Profiles of Key Companies in Clinical Supply Chain Management 49
11.1.1 Medidata 49
11.1.2 Catalent 49
11.1.3 Myoderm 49
11.1.4 Cold Chain Technologies 49
11.1.5 Numoda Corporation 49
11.1.6 Fisher Clinical Services 50
11.1.7 Marken 50
11.1.8 Phase Forward 50
11.1.9 Bilcare Global Clinical Supplies 50
11.1.10 Almac Clinical Services 50
11.1.11 BioClinica 51
11.1.12 Aptuit 51
11.1.13 Chiltern 51
11.2 Key Deals among Clinical Supply Management Companies 52
11.2.1 Medidata Solutions Acquired Clinical Force in July 2011 52
11.2.2 Catalent Acquires Clinical Trial Supplies Division of Aptuit LLC in February 2012 52
11.2.3 Ion Beam Applications (IBA) and Bayer Schering Pharma Sign a Deal in 2010 52

12 Clinical Supply Chain Management - Appendix 53
12.1 Market Definitions 53
12.2 Abbreviations 53
12.3 Bibliography 54
12.4 Research Methodology 55
12.4.1 Coverage 55
12.4.2 Secondary Research 55
12.4.3 Primary Research 56
12.4.4 Expert Panel Validation 56
12.5 Contact Us 56
12.6 Disclaimer 56

List of Tables


Table 1: Clinical Supply Chain Management, Clinical Trials in Different Geographies, %, 2012 10
Table 2: Clinical Supply Chain Management, R&D Expenditure Versus Turnover for the Top Ten Pharmaceutical Companies, 2011 27

List of Figures


Figure 1: Clinical Supply Chain Management, Investigational Medicinal Products (IMP) Path, 2012 9
Figure 2: Clinical Supply Chain Management, Clinical Trials in Different Geographies, %, 2012 10
Figure 3: Clinical Supply Chain Management, Illustrative Supply Chain for Clinical Trial Materials, 2012 11
Figure 4: Clinical Supply Chain Management, Capital Requirement, Stages, 2012 12
Figure 5: Clinical Supply Chain Management, Advantages of Geographic Expansion of Clinical Trials, 2012 14
Figure 6: Clinical Supply Chain Management, Types of Clinical Trial Material Packaging, 2012 17
Figure 7: Clinical Supply Chain Management, Key Stages in Distribution of Clinical Trial Material, 2012 19
Figure 8: Clinical Supply Chain Management, Key Focus Areas for Logistics, 2012 20
Figure 9: Clinical Supply Chain Management, Distribution Models, 2012 21
Figure 10: Clinical Supply Chain Management, Segments of Distribution Model, 2012 22
Figure 11: Clinical Supply Chain Management, Inventory Management Stages, 2012 23
Figure 12: Clinical Supply Chain Management, Factors Resulting in Efficient Supply Chain, 2012 25
Figure 13: Clinical Supply Chain Management, R&D Expenditure Versus Turnover for the Top Ten Pharmaceutical Companies, 2011 26
Figure 14: Clinical Supply Chain Management, Key Factors Responsible for Study Timeline Reduction by SMOs, 2011 28
Figure 15: Clinical Supply Chain Management, Site Initiation Process, 2011 29
Figure 16: Clinical Supply Chain Management, Technologies Used for Forecasting, 2012 33
Figure 17: Clinical Supply Chain Management, Clinical Data Management System Flow, Global, 2012 34
Figure 18: Clinical Supply Chain Management, Use of IVRS in the Shipment Request Process for Inventory Management, 2011 37
Figure 19: Clinical Supply Chain Management, Cost Saved by Using IVRS - Reduction in Averages, 2011 39
Figure 20: Clinical Supply Chain Management, Cost of Over-Recruitment by 10% in Different Study Samples, 2011 40
Figure 21: Clinical Supply Chain Management, A Typical Clinical Trial Management System, 2011 42
Figure 22: Clinical Supply Chain Management, EU Legislations, 2011 44

Upcoming Reports:

Greece: quinces market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the quinces market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the quinces market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the main...
Preventable Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
The use of preventable vaccines is to avoid the occurrence of an infectious disease, which is preventable by the use of vaccines. The occurrence of death due to a vaccine-preventable disease is termed as vaccine-preventable death, the reason being failure to attain vaccines in time, lack of access to vaccines and financial limitations. The WHO has estimated that in the year 2008, around 1.5 million deaths in the children aged less than 5 years were due to vaccine-preventable diseases. This accounted for about 17% of the global mortality of children aged less than 5 years. Further, it also...
Specialty Pigments - Global Forecast, Market Share, Trends, Size, Growth And Industry Analysis, 2012 - 2018
By - Transparency Market Research
Description Specialty pigments are a class of color additives that are used for enhancing product value and product performance in their application segments. The metallic and special color-shifting effect of specialty pigments has made them popular among consumers. They are primarily used for high-end products and attractive packaging. The application areas of specialty pigments include paints and coatings, plastics, printing inks, cosmetics, and toiletries.  The specialty pigment market is showing a promising growth due to its high performance as well as...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Bristol-Myers Squibb Posts USD 3.9 billion Revenues in 2014 Second Quarter
Jul 30, 2014  
Leading bio-pharmaceutical company Bristol-Myers Squibb has registered revenues of USD 3.9 billion in the 2014 second quarter. This marks a 4% decrease from the same period in 2013. The global revenues of the company (excluding the divested Diabetes Alliance), saw a 7% increase. In this quarter, the company’s results were underlined by steady global sales of nearly each of its...
Novartiss Simbrinza gets approval from the EU
Jul 30, 2014  
Glaucoma patients in Europe can easily obtain Novartis’ Simbrinza eye drops which are a combination of brimonidine tartrate and brinzolamide and it is without a beta-blocker. This eye drop has got the approval of the European Commission. Unlike the inefficient treatment provided by monotherapy, this eye drop aims at treating intraocular pressure or IOP in adults with ocular hypertension...
Second Treaty Between Zealand And Boehringer Ingelheim
Jul 30, 2014  
Denmark based Pharma group Zealand Pharma and Germany’s Boehringer Ingelheim have signed an accord to formulate new medicines for advanced and effective treatment of cardio-metabolic maladies. The collaboration between these two Pharma groups involves a new therapeutic peptide project from the list of preclinical programs of Zealand Pharma.  Both these companies are aiming...
Fresh Lawsuits Hit General Motors
Jul 30, 2014  
This Tuesday, a lawsuit has hit General Motors on behalf of nearly 650 people regarding the faulty ignition switches in a number of cars, the reason why these cars were recalled from customers, which led to accidents that injured and even killed people.  The lawsuit was filed in the federal court of Manhattan, where dozens of cases against the company over the issue of faulty ignition...
Export market in New Zealand driven by innovative and high-value food products
Jul 29, 2014  
Demand for beverages and high value foods in Asia are driving the food and beverage industry in New Zealand. Also there is high demand for dairy products, seafood, meat and processed foods in the Asian economies which fuel the give an export boost to the economy of New Zealand.  Asia has a rapidly growing market for food which in turn is highly beneficial for New Zealand’s export...